HCPCS G9203: Hepatitis C RNA Testing Documented Within 12 Months - OpenPayer

Summary & Overview

HCPCS G9203: Hepatitis C RNA Testing Documented Within 12 Months

HCPCS Level II code G9203 denotes documentation that hepatitis C virus (HCV) RNA testing was performed and recorded within 12 months before initiation of antiviral therapy. This measure is clinically important because RNA confirmation is necessary to verify active HCV infection prior to starting direct-acting antiviral treatment and supports appropriate care pathways and payer coverage decisions. Nationally, consistent capture of pre-treatment RNA testing aids quality measurement, prior authorization workflows, and accurate claims documentation.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents, typical service setting and clinical context, and an overview of topics commonly addressed alongside this code: billing and documentation expectations for pre-treatment HCV RNA testing, how payers commonly recognize laboratory confirmation in prior authorization and quality reporting, and related coding considerations. The publication highlights where to look for benchmarks and policy updates affecting use of G9203, and identifies gaps where input data was not provided.

This summary is intended for a national audience of billing professionals, clinicians involved in HCV care, and payer policy analysts seeking concise context about HCPCS Level II code G9203 and its role in documenting pre-treatment HCV RNA testing.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9203HCPCS Level IIhepatitis CHCV RNA testingpre-treatment testinglaboratoryquality measureprior authorization

Billing Code Overview

HCPCS Level II code G9203 documents that RNA testing for hepatitis C was performed and recorded within 12 months prior to initiating antiviral treatment for hepatitis C. This code captures the presence of a qualifying laboratory test result confirming HCV RNA testing in the medical record at the time treatment is started.

Service type: Laboratory confirmation / pre-treatment diagnostic testing

Typical site of service: Outpatient clinic, hospital outpatient department, or ambulatory laboratory settings

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 54-year-old patient with chronic hepatitis C virus (HCV) infection presents to a hepatology clinic to initiate direct-acting antiviral therapy. The clinician documents prior HCV RNA quantitative testing performed nine months earlier showing detectable HCV RNA, genotype confirmed, and baseline viral load documented in the electronic medical record. The clinical workflow includes verification of prior RNA testing within 12 months, review of results for active viremia and genotype, medication reconciliation, assessment for drug interactions and baseline labs (hepatic panel, CBC, creatinine), patient counseling, and electronic order entry for antiviral therapy. Documentation includes the date of the prior RNA assay, laboratory performing the test, and result values to support billing for G9203 which denotes RNA testing for hepatitis C documented as performed within 12 months prior to initiation of antiviral treatment for hepatitis C.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable E/M service by the same physician on the same day as a procedure	Use when a distinct evaluation and management visit is performed the same day as initiation of therapy and relevant to documenting medical necessity separate from billing.

HCPCS G0414: Open Treatment of Anterior Pelvic Bone Fracture with Internal Fixation

HCPCS-G9554-CHEST-NECK-CT-CTA-MRI-MRA-FOLLOW-UP-REPORTING

HCPCS G9554: Final Report for Chest/Neck CT, CTA, MRI, MRA with Follow-Up Recommendation

HCPCS-G0041-PATIENT-DECLINES-REFERRAL

HCPCS G0041: Patient and/or Care Partner Decline Referral

HCPCS-G9643-ELECTIVE-SURGERY

HCPCS G9643: Elective Surgery

HCPCS-G9156-WHEELCHAIR-EVALUATION-FACE-TO-FACE-PHYSICIAN

HCPCS G9156: Evaluation for Wheelchair, Face-to-Face Physician

HCPCS-G9389-POSTERIOR-CAPSULE-RUPTURE-VITRECTOMY-DURING-CATARACT-SURGERY

HCPCS G9389: Unplanned Posterior Capsule Rupture Requiring Vitrectomy

HCPCS-G9266-MAINTENANCE-HEMODIALYSIS-NO-CATHETER-90-DAYS

HCPCS G9266: Maintenance Hemodialysis ≥90 Days Without Catheter

HCPCS-G8540-FUNCTIONAL-OUTCOME-ASSESSMENT-NOT-ELIGIBLE

HCPCS G8540: Functional Outcome Assessment Not Eligible

HCPCS-G9246-HIV-CARE-CONTINUITY-MISSED-ELIGIBLE-ENCOUNTERS

HCPCS G9246: Missed HIV Care Continuity Encounters

HCPCS-G9785-PATHOLOGY-REPORT-CUTANEOUS-SKIN-CANCER-NOTIFICATION

HCPCS G9785: Pathology Report for Cutaneous Skin Cancer Notification

Showing 1–10 of 1996

G9203

Taxonomy Code	Specialty	Notes
`208000000X`	Gastroenterology	Hepatologists and gastroenterologists commonly manage HCV patients and initiate antiviral therapy.
`208000000S`	Hepatology (subspecialty of gastroenterology)	Specialists focused on liver disease who assess prior RNA testing and start treatment.
`207Q00000X`	Infectious Disease	Infectious disease physicians frequently treat HCV and interpret RNA testing in treatment decisions.
`208000000U`	Internal Medicine	Hospitalists or internists in outpatient practice may initiate antiviral therapy and document prior testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B18.2`	Chronic viral hepatitis C	Primary diagnosis indicating chronic HCV infection; most directly supports RNA testing and initiation of antiviral therapy.
`B19.20`	Unspecified viral hepatitis C without hepatic coma	Acute or unspecified presentation where HCV RNA testing is used to confirm viremia before treatment decisions.
`Z71.7`	Human immunodeficiency virus [HIV] counseling	Relevant when co-management or counseling occurs; HIV testing and co-infection considerations affect HCV treatment planning.
`Z11.59`	Encounter for screening for other viral diseases	May be used when initial screening results lead to confirmatory RNA testing documented prior to treatment.
`R76.8`	Other specified abnormal immunological findings	Sometimes used for abnormal serologic markers prompting RNA confirmation prior to initiating therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80053`	Comprehensive metabolic panel	Baseline hepatic and renal function testing commonly performed before initiating HCV antiviral therapy; complements documentation of readiness for treatment.
`80061`	Lipid panel	Baseline metabolic assessment often included with pre-treatment labs for medication safety.
`87520`	Infectious agent detection by nucleic acid (HCV), amplified probe technique, quantification	Laboratory technique CPT often used for HCV RNA quantification; directly related to the RNA testing referenced by `G9203` when billed by labs that also submit CPT-coded claims.
`87408`	Infectious agent antigen detection by nucleic acid (HCV), genotyping or sequencing (single target)	HCV genotype testing frequently performed in the pre-treatment workup to guide antiviral selection.
`99406`	Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes	Counseling services that may be provided during visits when initiating HCV therapy; reportable separately when applicable.
`99490`	Chronic care management services, at least 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month	Care coordination services that may encompass documentation review (including prior RNA testing) and ongoing management during antiviral therapy.

OpenPayer